Psychedelic Research Recap: May 2026

May added 31 psychedelic research papers to the Blossom database.

The month was unusually weighted towards patient-facing work, with controlled studies in depression, suicidal ideation, cocaine use disorder, and esketamine relapse prevention sitting alongside qualitative reports from opioid recovery and ayahuasca settings.

The rest of the set focused on human mechanisms, trial interpretation, clinical practice, naturalistic use, and one preclinical pain study.

Clinical and Patient Studies

Patient-facing papers carried much of May. The strongest direct evidence came from controlled or randomised studies, while several smaller studies asked how benefits might last, relapse might be prevented, or biological signals might change after treatment. The qualitative papers in this group are useful for lived experience and support needs, but they should not be read as efficacy tests.

A psilocybin trial in cocaine use disorder randomised 40 participants to a single 25 mg/70 kg dose with psychotherapy or to diphenhydramine as an active placebo. The psilocybin group had more cocaine-free days and a longer time to relapse. The sample was small, but this is still a notable controlled signal in a condition where medication options remain limited.

In a Swedish psilocybin trial, 35 people with moderate to severe recurrent major depression received either 25 mg psilocybin or niacin with the same psychotherapy structure. Psilocybin reduced clinician-rated depression more than niacin (vitamin B3) by day 8, with some effects lasting beyond three months on self-report measures. The paper also keeps the result in perspective: blinding was poor, the sample was modest, and two participants had severe persistent anxiety that required medical attention.

The EPIsoDE follow-up looked at longer-term outcomes after a Phase IIb trial of psilocybin with psychotherapy for treatment-resistant depression. Across 126 participants with six- or twelve-month data, depression scores remained lower than baseline after one or two 25 mg doses, with no clear difference between dosing sequences. Because the follow-up was naturalistic and lacked a continuing placebo comparison, it is best read as durability evidence from an earlier trial line rather than as a fresh controlled efficacy result.

A ketamine and buprenorphine trial tested whether low-dose sublingual buprenorphine could extend anti-suicidal effects after ketamine in 50 adults with major depression and suicidal thoughts. Compared with placebo, buprenorphine produced a greater and longer-lasting reduction in suicidal ideation, while depression scores were similar between groups. No serious treatment-related side effects were reported, making the study a focused attempt to separate anti-suicidal effects from broader antidepressant change.

The CBT-ENDURE trial asked whether cognitive behavioural therapy could help maintain gains after esketamine in people with major depression and suicidal ideation. In 93 participants, adding 16 weeks of CBT was feasible and reduced suicidal thoughts and depression scores more than esketamine with usual care alone. The study did not find a difference in suicide-related events, so the main signal is about symptom maintenance and structured follow-up care.

An alcohol use disorder methylation analysis used data from an earlier psilocybin-assisted relapse-prevention trial in detoxified patients. In 37 participants, the study found one psilocybin-linked methylation site and broader pathway signals related to neuroplasticity, immune function, depression, and drinking measures. This is a secondary analysis, so it is better treated as exploratory biology than as evidence that methylation changes explain clinical benefit.

An open-label psilocybin study tested a single 25 mg dose with psychological support in 20 people with chronic suicidal ideation. Suicidal thoughts and depression fell rapidly and remained lower over 12 weeks, with no serious adverse events reported. The absence of a control group matters here, especially given the intensity of support and expectancy around treatment.

An LSD white matter analysis returned to a depression trial that compared two low-dose sessions with a higher-dose sequence of 100 micrograms followed by 200 micrograms. The higher-dose group showed white matter changes on brain scans that were linked with later symptom improvement. As a secondary analysis, it belongs with the patient studies but should be read as a mechanistic signal from earlier trial data.

An ibogaine interview study described the experiences of ten opioid-dependent people in New Zealand who used ibogaine for detoxification. Participants reported rapid withdrawal relief, better mood, less anxiety, and in some cases sustained abstinence. Relapse still occurred, and participants repeatedly pointed to screening, preparation, and post-treatment support as part of the outcome.

A qualitative ayahuasca study interviewed nine people in Brazil about ceremonial use and suicidal thoughts or behaviour. Participants described stronger wellbeing and reduced suicidality, particularly in neoshamanic settings. The study is useful context for how ritual, support, and personal meaning can shape perceived change, but it remains exploratory and self-reported.

Mechanisms and Brain Measures

Several articles asked what psychedelic states do to perception, brain dynamics, speech, sleep, and imaging signals. These studies are often smaller than the patient trials, and many are designed to improve measurement rather than test treatment benefit. Their value is in making mechanisms and methods more concrete.

A DMT receptor-blockade study tested 12 healthy volunteers with oral pindolol before a low intravenous DMT dose. Blocking the 5-HT1A receptor intensified subjective effects, suggesting that this receptor helps shape how DMT is experienced. The design was small but tightly controlled, making it a useful human pharmacology paper rather than a clinical one.

A first-use psilocybin neuroimaging study followed 28 psychedelic-naive participants in a placebo-controlled, within-subject design. A 25 mg dose produced lasting functional and anatomical brain changes from one hour to one month, alongside higher cognitive flexibility, psychological insight, and wellbeing at one month. The paper connects acute signal entropy, next-day insight, and later wellbeing, but it remains a small mechanistic study in healthy volunteers.

A DMT secondary analysis reported that vaporised DMT increased psychotic-like experiences and suggestibility in 25 healthy volunteers, together with strong mystical and other psychedelic effects. The relationships among those effects appeared to be driven more by positive emotionality than by mystical experience alone. That makes the paper a careful re-analysis of acute experience, not a claim that DMT models or treats psychosis.

An EEG microstate analysis compared psilocybin microdosing with acute inhaled DMT across two existing studies. Frequency-specific analysis detected changes that broader EEG summaries could miss, with subtle effects for psilocybin microdosing and wider shifts during DMT. The main contribution is methodological: it shows one way to separate different kinds of resting-state brain dynamics.

The PsiConnect dataset paper introduced an open multimodal resource from 63 healthy adults who received 19 mg psilocybin during MRI and EEG sessions. The protocol compared rest, guided meditation, music, and movie watching, with behavioural follow-up extending to twelve months. The paper is mainly a data and methods resource, including quality-control work showing that multi-echo fMRI and ME-ICA improved signal quality in difficult brain regions.

A chronic cluster headache study examined sleep and brain microstructure in 11 patients given three psilocybin doses of 10 mg/70 kg. Participants reported better sleep and fewer headache attacks after treatment, while brain microstructure measures did not show clear average changes. The open-label design and very small sample mean the sleep finding is promising but still early.

An ayahuasca fMRI analysis used persistent homology, a way of studying the shape of network connectivity, in nine participants before and after ayahuasca. The main analysis found a small drop in one measure of topological complexity, but the result did not survive correction and was not robust across analytic choices. This is a narrow exploratory imaging paper, useful mostly for method development.

Safety and Trial Interpretation

May also brought papers that affect how clinical signals should be interpreted. Some focused on masking and expectancy, while others examined cardiovascular, manic, or acute adverse events. These papers do not carry the excitement of efficacy trials, but they are central to judging what future studies need to measure.

A blinding integrity trial in 120 healthy volunteers compared psilocybin, MDMA, and methylphenidate as an active placebo. Blinding was generally insufficient, with functional unblinding strongest for psilocybin, moderate for MDMA, and lowest for methylphenidate. The result reinforces a familiar problem in psychedelic trials: subjective effects can make allocation easier to guess even when the study is formally blinded.

A mania systematic review synthesised 23 studies or reports on manic and hypomanic symptoms after serotonergic psychedelics or MDMA. Rates ranged from about 6% in controlled psilocybin trials to 30% in naturalistic studies of people with bipolar disorder, with symptoms usually acute and self-limited. The review does not show that psychedelics commonly cause mania, but it clarifies why bipolar I disorder, family vulnerability, polysubstance use, and unsupervised use deserve close attention.

An All of Us valvular heart analysis used electronic health record data from 286,842 US adults to ask whether lifetime hallucinogen use was associated with valvular heart disease. After adjustment, lifetime use was linked to a small increase in odds, although the exposure category combined several substances and the cross-sectional design cannot show timing or causality. The paper is best treated as hypothesis-generating cardiovascular safety work.

A psilocybin syncope case report described a healthy 35-year-old man who fainted after taking 25 mg oral psilocybin in an open-label brain function study. Low blood pressure, rapid heartbeat, and sweating were consistent with neurocardiogenic syncope, and he recovered quickly with simple supportive care. It is a rare event, but a practical reminder to monitor hypotension and fainting as well as hypertension.

Practice and Support Models

A separate group of papers looked at how psychedelic care is delivered, understood, and supported. These studies are mostly surveys, interviews, or qualitative syntheses, so they describe current practice and experience rather than testing clinical efficacy. Together, they point to a recurring issue: preparation, integration, access, training, and cost shape what treatment can become outside trials.

An investigator interview study asked 21 US psychedelic clinical researchers how treatments such as MDMA and psilocybin might move from trials into routine care. Participants saw major challenges around the role of psychotherapy, treatment cost, scalability, public enthusiasm, and stigma. The paper is useful because it treats implementation as part of the evidence problem, not only as a later delivery question.

A Swiss physician survey described psychedelic-assisted therapy under legal exemptions, mainly for depression, anxiety, PTSD, and chronic pain. Forty-one physicians reported wide variation in practice, with psilocybin, MDMA, and LSD commonly used, music often included, and preparation and integration treated as routine. Reported adverse effects included disorientation, feeling cold, anxiety, and nausea.

A palliative care physician study surveyed 93 Australasian doctors and interviewed a smaller group about psychedelic medicines. Most respondents did not agree that psychedelics should remain prohibited for medical use, and 88% agreed that clinical use in palliative patients warrants further investigation. The qualitative themes were measured rather than promotional, centred on openness to innovation, safety, access, and equity.

A psychotherapy-after-challenges study interviewed 35 people who sought therapy after difficult naturalistic psychedelic experiences. Many felt misunderstood, judged, or poorly supported, and some hid their distress or turned to self-directed support instead. The paper makes a practical point for integration care: therapy can fail when clinicians and clients do not share a workable language for distress after psychedelics.

An eating disorders meta-synthesis brought together eight qualitative studies of psychedelic treatment experiences from patients and providers. Perceived benefits centred on emotional processing and a stronger connection with the body and self. The review also highlights specific risks, including low weight and medical vulnerability, and argues for eating-disorder-specific preparation, support, and integration rather than generic protocols.

Naturalistic Use and Early Work

The remaining papers were less directly clinical but still help round out the month. They covered retreat settings, recreational intention-setting, social attitudes, speech markers, and a rat model of pain. Most should be read as context or early-stage mechanism work rather than evidence for treatment efficacy.

An authoritarian attitudes re-analysis found no clear attitude change after psychedelic use across three datasets: people planning to take psychedelics, healthy volunteers given psilocybin, and patients with depression in a randomised trial. It is a useful null result because it pushes back against broad claims that psychedelics reliably shift political attitudes in one direction.

A Shipibo-led ayahuasca retreat study followed 264 Western participants for twelve months. Quality of life and decentering improved, neuroticism fell, extraversion rose, and most participants reported lasting benefits, with minimal adverse effects. Because this was an observational retreat study, the ceremonial, cultural, and social setting is part of what was studied rather than background noise.

An intention-setting survey asked 562 recreational psychedelic users about the intentions behind their most meaningful experience. The most common themes were personal growth and healing, and people who described relevant and integrated intentions tended to report larger wellbeing improvements. The design was retrospective, so the result shows associations in memory and meaning-making rather than a prospective test of intention-setting.

A 5-MeO-DMT speech study analysed daily voice journals from 29 people before and after a retreat. Speech shifted towards more cognitive and less social language, and voice quality also changed. Baseline speech patterns helped predict preparedness, emotional breakthrough, and later wellbeing, making the paper a small naturalistic attempt to measure psychological change through language.

A rat study of LSD and pain found that a single dose persistently reduced the emotional, rather than sensory, component of pain. The effect was linked to the anterior cingulate cortex, where LSD dampened pain-related responses and reduced encoding of aversive value. This is preclinical work, so it belongs at the end of the clinical evidence chain even though the mechanism is interesting.